Prophylactic Use of LMWH vs UFH in PE Patients

As a result of deep vein thrombosis (DVT), a pulmonary embo­lism (PE) can occur which creates a blockage in the body’s pulmonary circulation, leading to cell death. PE is the third leading cause of death in the U.S., while being the most common, most preventable cause of death in hospitalized patients. Understanding the signs and symptoms of PE is essential in order to save patients’ lives. The objective of this research study was to compare the prophylactic use of Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH) in patients effected with PE. Information for this research project was gathered using a quantitative systemic review and meta-analysis approach. Data was collected from mul­tiple research studies and combined to identify the best approach for prophylactic treatment of PE. The findings of this study concluded that LMWH is overall more beneficial to patients with PE than UFH for many reasons. Because each dose is based on the patient’s weight, LMWH can reduce the frequency of lab testing while giving them the ability to have anticoagulation therapy at home, thus, reducing the length of stay in the hospital. Prophylactic use of LMWH in PE patients can save the hospital and the patient thousands of dollars a year while consistently preventing and treating this complication